| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Catheter Precision, Inc. (VTAK - NYSE/American), a US based medical device company focused on developing technologically advanced products for the cardiac electrophysiology market today announced that the LockeT Compare Study has enrolled its first three patients.
The LockeT Compare Study is a single center, physician-initiated study that will enroll up to 100 patients and evaluate the safety profile of the LockeT suture retention device compared to internal closure devices. Groin complications after a cardiac catheter procedure, such as atrial fibrillation, are common and can range from small bruising to serious events such as embolism. To date, LockeT clinical data has shown that the product is safe, effective and reduces procedural cost without changing current hospital practices and workflows.
Posted In: VTAK
